Literature DB >> 22204910

Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.

Cécile Béguin1, Justin Potuzak, Wei Xu, Lee-Yuan Liu-Chen, John M Streicher, Chad E Groer, Laura M Bohn, William A Carlezon, Bruce M Cohen.   

Abstract

The kappa opioid receptor (KOPR) has been identified as a potential drug target to prevent or alter the course of mood, anxiety and addictive disorders or reduce response to stress. In a search for highly potent and selective KOPR partial agonists as pharmacological tools, we have modified 12-epi-salvinorin A, a compound which we have previously observed to be a KOPR partial agonist. Five analogues of 12-epi-salvinorin A were synthesized and their effects on G protein activation as well as β-arrestin2 recruitment were evaluated. Only 12-epi-salvinorin A (1) partially activated signaling through G proteins, yet acted as a full agonist in the β-arrestin 2 DiscoveRx assay. Other salvinorin analogues tested in these functional assays were full agonists in both assays of KOPR activation. By comparison, the non-selective opioid ligand nalbuphine, known to be a partial agonist for G-protein activation, was also a partial agonist for the β-arrestin mediated signaling pathway activated through KOPR.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22204910      PMCID: PMC3926198          DOI: 10.1016/j.bmcl.2011.11.128

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  24 in total

1.  Effectiveness of analogs of the kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) to reduce U50,488-induced diuresis and stress-induced cocaine reinstatement in rats.

Authors:  Patrick M Beardsley; Gerald T Pollard; James L Howard; F Ivy Carroll
Journal:  Psychopharmacology (Berl)       Date:  2010-04-07       Impact factor: 4.530

2.  Functional selectivity and biased receptor signaling.

Authors:  Terry Kenakin
Journal:  J Pharmacol Exp Ther       Date:  2010-10-28       Impact factor: 4.030

Review 3.  Kappa-opioid ligands in the study and treatment of mood disorders.

Authors:  William A Carlezon; Cécile Béguin; Allison T Knoll; Bruce M Cohen
Journal:  Pharmacol Ther       Date:  2009-06-02       Impact factor: 12.310

Review 4.  Kinase cascades and ligand-directed signaling at the kappa opioid receptor.

Authors:  Michael R Bruchas; Charles Chavkin
Journal:  Psychopharmacology (Berl)       Date:  2010-04-17       Impact factor: 4.530

5.  Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers.

Authors:  Thomas A Munro; Katharine K Duncan; Wei Xu; Yulin Wang; Lee-Yuan Liu-Chen; William A Carlezon; Bruce M Cohen; Cécile Béguin
Journal:  Bioorg Med Chem       Date:  2007-10-24       Impact factor: 3.641

6.  Ligand functional selectivity advances our understanding of drug mechanisms and drug discovery.

Authors:  Richard B Mailman; Vishakantha Murthy
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

7.  Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.

Authors:  Cécile Béguin; Katharine K Duncan; Thomas A Munro; Douglas M Ho; Wei Xu; Lee-Yuan Liu-Chen; William A Carlezon; Bruce M Cohen
Journal:  Bioorg Med Chem       Date:  2008-12-14       Impact factor: 3.641

Review 8.  The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors.

Authors:  M R Bruchas; B B Land; C Chavkin
Journal:  Brain Res       Date:  2009-08-28       Impact factor: 3.252

Review 9.  Dynorphin, stress, and depression.

Authors:  Allison T Knoll; William A Carlezon
Journal:  Brain Res       Date:  2009-09-24       Impact factor: 3.252

10.  The effects of pentazocine, a kappa agonist, in patients with mania.

Authors:  Bruce M Cohen; Beth Murphy
Journal:  Int J Neuropsychopharmacol       Date:  2007-09-26       Impact factor: 5.176

View more
  15 in total

1.  6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment.

Authors:  Marie-Laure Rives; Mary Rossillo; Lee-Yuan Liu-Chen; Jonathan A Javitch
Journal:  J Biol Chem       Date:  2012-06-26       Impact factor: 5.157

Review 2.  Clerodane diterpenes: sources, structures, and biological activities.

Authors:  Rongtao Li; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Nat Prod Rep       Date:  2016-07-18       Impact factor: 13.423

3.  The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats.

Authors:  Aashish S Morani; Amy Ewald; Katherine M Prevatt-Smith; Thomas E Prisinzano; Bronwyn M Kivell
Journal:  Eur J Pharmacol       Date:  2013-11-04       Impact factor: 4.432

4.  A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models.

Authors:  Wei Lei; Rakesh H Vekariya; Subramaniam Ananthan; John M Streicher
Journal:  J Pain       Date:  2019-06-12       Impact factor: 5.820

Review 5.  A review of salvinorin analogs and their kappa-opioid receptor activity.

Authors:  Jeremy J Roach; Ryan A Shenvi
Journal:  Bioorg Med Chem Lett       Date:  2018-03-12       Impact factor: 2.823

Review 6.  Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.

Authors:  Bronwyn M Kivell; Amy W M Ewald; Thomas E Prisinzano
Journal:  Adv Pharmacol       Date:  2014

7.  Intrinsic relative activities of κ opioid agonists in activating Gα proteins and internalizing receptor: Differences between human and mouse receptors.

Authors:  Kelly M DiMattio; Frederick J Ehlert; Lee-Yuan Liu-Chen
Journal:  Eur J Pharmacol       Date:  2015-06-06       Impact factor: 4.432

8.  Semisynthetic neoclerodanes as kappa opioid receptor probes.

Authors:  Kimberly M Lovell; Tamara Vasiljevik; Juan J Araya; Anthony Lozama; Katherine M Prevatt-Smith; Victor W Day; Christina M Dersch; Richard B Rothman; Eduardo R Butelman; Mary Jeanne Kreek; Thomas E Prisinzano
Journal:  Bioorg Med Chem       Date:  2012-03-01       Impact factor: 3.641

9.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

Authors:  Yan Zhang; Amanda Braithwaite; Yunyun Yuan; John M Streicher; Edward J Bilsky
Journal:  Eur J Pharmacol       Date:  2014-05-08       Impact factor: 4.432

10.  Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands.

Authors:  Prabhakar R Polepally; Kate White; Eyal Vardy; Bryan L Roth; Daneel Ferreira; Jordan K Zjawiony
Journal:  Bioorg Med Chem Lett       Date:  2013-04-04       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.